A new government-run discount medicine website is set to launch this month. It's called TrumpRx: A direct-to-consumer drug ...
Without greed, we wouldn’t have many of the benefits we enjoy today, such as cars, heated homes and computers, argue our ...
Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...
WELCOME TO 2026: As the capital jolts back to life after a much-needed break, the city’s lobbyist class is preparing for a ...
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) stock falls amid market uptick: What investors need to know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $469.68, marking a -2.99% move from the previous day.
The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry.Deep ...
Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.
Pharma faces regulations and stringent rules for transparency, but the payoff is drugs that can get to market faster and ...
As of Friday, January 02, Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 60.00%, which has investors ...
India's Torrent Pharmaceuticals is set to raise up to 125 billion rupees ($1.4 billion) through short-duration bond sales in January, in one of the latest acquisition-funding deals, two bankers said.
Zacks Investment Research on MSN
Vertex Pharmaceuticals Incorporated (VRTX) is attracting investor attention: Here is what you should know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results